The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Komboglyze saxagliptin;metformin hydrochloride | AstraZeneca AB | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2011-11-24 | Order → |
| Onduarp telmisartan;amlodipine | Boehringer Ingelheim International GmbH | Hypertension | 🇪🇺 EU 2011-11-24 | Order → |
| Rasitrio aliskiren;amlodipine;hydrochlorothiazide | Novartis Europharm Ltd. | Hypertension | 🇪🇺 EU 2011-11-22 | Order → |
| Ioa nomegestrol acetate;estradiol | Organon N.V. | Contraception | 🇪🇺 EU 2011-11-16 | Order → |
| Vyndaqel tafamidis OrphanExceptional circumstancesAdditional monitoring | Pfizer Europe MA EEIG | Amyloidosis | 🇪🇺 EU 2011-11-16 | Order → |
| Plenadren hydrocortisone | Takeda Pharmaceuticals International AG Ireland Branch | Adrenal Insufficiency | 🇪🇺 EU 2011-11-03 | Order → |
| Eurartesim piperaquine tetraphosphate;artenimol | Alfasigma S.p.A. | Malaria | 🇪🇺 EU 2011-10-27 | Order → |
| Levetiracetam Accord levetiracetam Generic | Accord Healthcare S.L.U. | Epilepsy | 🇪🇺 EU 2011-10-03 | Order → |
| Levetiracetam Actavis levetiracetam Generic | Actavis Group PTC ehf | Epilepsy | 🇪🇺 EU 2011-10-03 | Order → |
| Matever levetiracetam Generic | Pharmathen S.A. | Epilepsy | 🇪🇺 EU 2011-10-03 | Order → |
| Telmisartan Teva Pharma telmisartan Generic | Teva B.V. | Hypertension | 🇪🇺 EU 2011-10-03 | Order → |
| Pramipexole Accord pramipexole Generic | Accord Healthcare S.L.U. | Parkinson Disease; Restless Legs Syndrome | 🇪🇺 EU 2011-09-29 | Order → |
| Incivo telaprevir Additional monitoring | Janssen-Cilag International | Hepatitis C, Chronic | 🇪🇺 EU 2011-09-19 | Order → |
| Dexdor dexmedetomidine | Orion Corporation | Conscious Sedation | 🇪🇺 EU 2011-09-15 | Order → |
| Zytiga abiraterone Accelerated assessment | Janssen-Cilag International | Prostatic Neoplasms | 🇪🇺 EU 2011-09-05 | Order → |
| Buccolam midazolam | Neuraxpharm Pharmaceuticals S.L. | Epilepsy | 🇪🇺 EU 2011-09-04 | Order → |
| Vibativ telavancin Additional monitoring | Theravance Biopharma Ireland Umited | Pneumonia, Bacterial; Cross Infection | 🇪🇺 EU 2011-09-02 | Order → |
| Votubia everolimus | Novartis Europharm Limited | Tuberous Sclerosis | 🇪🇺 EU 2011-09-02 | Order → |
| Levetiracetam ratiopharm levetiracetam Generic | ratiopharm GmbH | Epilepsy | 🇪🇺 EU 2011-08-26 | Order → |
| Levetiracetam Teva levetiracetam Generic | Teva B.V. | Epilepsy | 🇪🇺 EU 2011-08-25 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.